What if the solution to Alzheimer’s disease lies not in combating the proteins that cause it, but in simply getting more ...

Researchers from Washington University in St. Louis found people who took suvorexant, a common treatment for insomnia, for ...

A study from Washington University in St. Louis found taking suvorexant, a common insomnia medication, for two nights ...

Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...

This review provides an overview of Alzheimer’s disease (AD), discussing its complex pathophysiology, risk factors, and ...

Preclinical studies have shown AT-02 is able to bind to multiple amyloid types and can induce macrophage mediated amyloid phagocytosis and removal. The Food and Drug Administration has granted Orphan ...

Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 ...

Dennis J. Selkoe, M.D. The Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical School. Co-Director, Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s ...

A new gene editing tool that helps cellular machinery skip parts of genes responsible for diseases has been applied to reduce the formation of amyloid-beta plaque precursors in a mouse model of ...

Immune cells in the brain called microglia can partially break down large amyloid plaques characteristic of Alzheimer's disease by latching on to them, forming a sort of external stomach and releasing ...